fbpx

Alfentanil

OVERVIEW

  • Alfentanil is a potent synthetic mu-opioid receptor agonist analgesic drug
  • It is a analogue of the synthetic opioid fentanyl that is only 10% as potent (on a weight-to-weight basis), but has quicker onset, quicker time to maximal effect, shorter duration of action (10 minutes), is more cardiovascularly stable and has more respiratory depression

PREPARATION

  • Ampoules: 1 mg / 2 mL or 5 mg/10 mL

DOSES

Bolus IV sedation:

  • The usual single IV bolus dose is around 5 -7 micrograms/ kg  (e.g. 350 – 700 micrograms for a 70kg adult)
  • further 2- 3micrograms/ kg doses q10-15min prn
  • Higher doses may be given to mechanically ventilated patients with airway protection

Anaesthetic induction

  • 10 – 50 mcg/ kg IV

MECHANISM OF ACTION

  • Alfentanil binds opioid receptors, and is most active at the mu receptors.
  • Effects are analesia, sedation, anxiolysis and induction of anaesthesia

PHARMACOKINETICS

  • Absorption – IV bolus or infusion with maximal effect in 1-2 minutes
  • Distribution – Vd varies from 0.4 to 1.0 L/kg (10% of that of fentanyl) due to  limited liposolubility and extensive plasma protein binding (mainly to alpha1-acid glycoprotein)
  • Metabolism – extensive liver metabolism
  • Elimination – only 1% excreted in the liver in active form

INDICATIONS

  • Adjunctive analgesia during anaesthetics for short duration procedures or longer duration proceudres (e.g. used as an infusion)
  • Stand alone sedation for short painful procedures in the Emergency Department

CONTRA-INDICATIONS/ PRECAUTIONS

  • Respiratory disease e.g. Severe obstructive airways disease, those at risk of upper airways obstruction, obstructive sleep apnea
  • Depressed conscious state or concomitant CNS depressant use
  • Hypotension
  • Hepatic impairment (risk of excessive sedation)
  • elderly (use lower doses)
  • infants <12 months ( more susceptible to respiratory depression, use lower doses)
  • allergy
  • pregnancy (fentanyl is category C)

ADVERSE EFFECTS (typical of opioids)

  • CNS
    • decreased conscious state, with attendant risk of airway compromise (may cause death)
    • Euphoria, dysphoria, delirium, hallucinations
    • lowers seizure threshold
  • RESP (increased with alfentanil cf fentanyl)
    • Respiratory depression or arrest (may cause death; synergistic with other respiratory depressants)
  • GI
    • Nausea and vomiting (due to stimulation of the chemoreceptor trigger zone – consider prophylactic antiemetics)
    • decreased GI motility with delay  in gastric emptying and constipation
  • CVS (decreased with alfentanil cf fentanyl)
    • Hypotension, bradycardia (especially with large or rapid IV boluses)
  • allergic reactions (uncommon), direct histamine release is rare for synthetic opioids such as alfentanil
  • urinary retention (increased bladder sphincter tone)
  • dependence, addiction, withdrawal, tolerance

ANTIDOTE

  • Naloxone

CCC Pharmacology Series

Critical Care

Compendium

Chris is an Intensivist and ECMO specialist at The Alfred ICU, where he is Deputy Director (Education). He is a Clinical Adjunct Associate Professor at Monash University, the Lead for the  Clinician Educator Incubator programme, and a CICM First Part Examiner.

He is an internationally recognised Clinician Educator with a passion for helping clinicians learn and for improving the clinical performance of individuals and collectives. He was one of the founders of the FOAM movement (Free Open-Access Medical education) has been recognised for his contributions to education with awards from ANZICS, ANZAHPE, and ACEM.

His one great achievement is being the father of three amazing children.

On Bluesky, he is @precordialthump.bsky.social and on the site that Elon has screwed up, he is @precordialthump.

| INTENSIVE | RAGE | Resuscitology | SMACC

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.